- Home
- HTB vs DNTH Comparison
HTB vs DNTH Comparison
Compare HTB & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTB
- DNTH
- Stock Information
- Founded
- HTB 1926
- DNTH 2015
- Country
- HTB United States
- DNTH United States
- Employees
- HTB N/A
- DNTH N/A
- Industry
- HTB
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- HTB
- DNTH Health Care
- Exchange
- HTB NYSE
- DNTH Nasdaq
- Market Cap
- HTB 636.8M
- DNTH 568.6M
- IPO Year
- HTB N/A
- DNTH N/A
- Fundamental
- Price
- HTB $39.07
- DNTH $18.85
- Analyst Decision
- HTB Buy
- DNTH Strong Buy
- Analyst Count
- HTB 1
- DNTH 8
- Target Price
- HTB $43.00
- DNTH $53.00
- AVG Volume (30 Days)
- HTB 55.9K
- DNTH 315.6K
- Earning Date
- HTB 07-23-2025
- DNTH 08-07-2025
- Dividend Yield
- HTB 1.23%
- DNTH N/A
- EPS Growth
- HTB N/A
- DNTH N/A
- EPS
- HTB 3.16
- DNTH N/A
- Revenue
- HTB $193,954,000.00
- DNTH $6,524,000.00
- Revenue This Year
- HTB $6.54
- DNTH N/A
- Revenue Next Year
- HTB $1.75
- DNTH N/A
- P/E Ratio
- HTB $12.36
- DNTH N/A
- Revenue Growth
- HTB 0.68
- DNTH 102.36
- 52 Week Low
- HTB $28.53
- DNTH $13.37
- 52 Week High
- HTB $39.07
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- HTB N/A
- DNTH 54.07
- Support Level
- HTB N/A
- DNTH $17.27
- Resistance Level
- HTB N/A
- DNTH $19.46
- Average True Range (ATR)
- HTB 0.00
- DNTH 1.07
- MACD
- HTB 0.00
- DNTH 0.15
- Stochastic Oscillator
- HTB 0.00
- DNTH 76.74
About HTB HOMETRUST BANCSHARES INC
HomeTrust Bancshares Inc operates as a bank holding company. It engaged in the business of planning, directing and coordinating the business activities of the Bank. The Bank is a North Carolina state chartered bank and provides a range of retail and commercial banking products. Company's principal business consists of attracting deposits from the general public and investing those funds, along with borrowed funds, in commercial real estate loans, construction and development loans, commercial and industrial loans, equipment finance leases, municipal leases, loans secured by first and second mortgages on one-to-four family residences including home equity loans and other consumer loans.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.